BDNF Val66Met variants and brain volume changes in non-affective psychosis patients and healthy controls: A 3year follow-up study

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 45, Issue , 2013, Pages 201-206

  Suárez Pinilla, Paula ^a,b   Roiz Santiáñez, Roberto ^a,b   de la Foz, Victor Ortiz García ^a,b   Mata, Ignacio ^a,b   Fañanas, Lourdes ^b,c   Brambilla, Paolo ^d,e   Ruíz Pérez, Eva ^a   Crespo Facorro, Benedicto ^a,b  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d UNIVERSITY OF UDINE   (Italy)

^e UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

BDNF; First episode psychosis; Follow up, genetics; Imaging genomics; Longitudinal; Magnetic resonance imaging

Indexed keywords

ALCOHOL; ARIPIPRAZOLE; BRAIN DERIVED NEUROTROPHIC FACTOR; HALOPERIDOL; METHIONINE; OLANZAPINE; QUETIAPINE; RISPERIDONE; VALINE; ZIPRASIDONE;

ADOLESCENT; ADULT; ALCOHOL CONSUMPTION; ARTICLE; BDNF GENE; BRAIN SIZE; BRIEF PSYCHOTIC DISORDER; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON AFFECTIVE PSYCHOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PSYCHOSIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SPAIN;

BDNF; BPRS; BRAIN DERIVED NEUROTROPHIC FACTOR; BRIEF PSYCHIATRIC REPORT SCALE; CORTICAL CEREBROSPINAL FLUID; CSF; DAS; DISABILITY ASSESSMENT SCHEDULE; FEP; FIRST EPISODE OF PSYCHOSIS; FIRST-EPISODE PSYCHOSIS; FOLLOW-UP, GENETICS; GM; GRAY MATTER; HARDY WEINBERG EQUILIBRIUM; HWE; IMAGING GENOMICS; LONGITUDINAL; MAGNETIC RESONANCE IMAGING; MET; METHIONINE; MRI; SANS; SAPS; SCALE FOR THE ASSESSMENT OF POSITIVE SYMPTOMS; SCALE FOR THE ASSESSMENT OF THE NEGATIVE SYMPTOMS; SINGLE NUCLEOTIDE POLYMORPHISM; SNP; VAL; VALINE; WHITE MATTER; WM;

ADOLESCENT; ADULT; BRAIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NEUROIMAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHOTIC DISORDERS;

EID: 84880299629     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2013.05.014     Document Type: Article

References (68)

1. Allen S.J., Dawbarn D. Clinical relevance of the neurotrophins and their receptors. Clin Sci (Lond) 2006, 110(2):175-191.
2. Amminger G.P., Harris M.G., Conus P., Lambert M., Elkins K.S., Yuen H.P., et al. Treated incidence of first-episode psychosis in the catchment area of EPPIC between 1997 and 2000. Acta Psychiatr Scand 2006, 114:337-345.
3. Andreasen N.C. Scale for the Assessment of Positive Symptoms: (SAPS) 1984, University of Iowa.
4. Andreasen N.C. Scale for the Assessment of Negative Symptoms: SANS 1984, Department of Psychiatry, College of Medicine, the University of Iowa.
5. Andreasen N.C., Cohen G., Harris G., Cizadlo T., Parkkinen J., Rezai K., et al. Image processing for the study of brain structure and function: problems and programs. J Neuropsychiatry Clin Neurosci 1992, 4:125-133.
6. Andreasen N.C., Rajarethinam R., Cizadlo T., Arndt S., Swayze V.W., Flashman L.A., et al. Automatic atlas-based volume estimation of human brain regions from MR images. J Comput Assist Tomogr 1996, 20:98-106.
7. Bath K.G., Lee F.S. Variant BDNF (Val66Met) impact on brain structure and function. Cogn Affect Behav Neurosci 2006, 6:79-85.
8. Biskupska J., Borowiak K., Karlin-Grazewicz K., Janus T., Waloszczyk P., Potocka-Banas B., et al. Estimation of BDNF gene polymorphism and predisposition to dependence development for selected psychoactive compounds: genetic aspects of addiction with the selected drugs, amphetamine, tetrahydrocannabinol and opiates. Hum Exp Toxicol 2012, 32(3):236-240.
9. Buckley P.F., Pillai A., Howell K.R. Brain-derived neurotrophic factor: findings in schizophrenia. Curr Opin Psychiatry 2011, 24(2):122-127. [Mar].
10. Bueller J.A., Aftab M., Sen S., Gomez-Hassan D., Burmeister M., Zubieta J.-K. BDNF Val66Met allele is associated with reduced hippocampal volume in healthy subjects. Biol Psychiatry 2006, 59:812-815.
11. Cahn W., Hulshoff Pol H.E., Lems E.B.T.E., Van Haren N.E.M., Schnack H.G., Van der Linden J.A., et al. Brain volume changes in first-episode schizophrenia: a 1-year follow-up study. Arch Gen Psychiatry 2002, 59:1002-1010.
12. Chang H.A., Lu R.B., Shy M.J., Chang C.C., Lee M.S., Huang S.Y. Brain-derived neurotrophic factor Val66Met polymorphism: association with psychopathological symptoms of schizophrenia?. J Neuropsychiatry Clin Neurosci 2009, 21(1):30-37.
13. Chen Z.-Y., Patel P.D., Sant G., Meng C.-X., Teng K.K., Hempstead B.L., et al. Variant brain-derived neurotrophic factor (BDNF) (Met66) alters the intracellular trafficking and activity-dependent secretion of wild-type BDNF in neurosecretory cells and cortical neurons. J Neurosci 2004, 24:4401-4411.
14. Crespo-Facorro B., Roiz-Santiáñez R., Pelayo-Terán J.M., González-Blanch C., Pérez-Iglesias R., Gutiérrez A., et al. Caudate nucleus volume and its clinical and cognitive correlations in first episode schizophrenia. Schizophr Res 2007, 91:87-96.
15. Crespo-Facorro B., Roiz-Santiáñez R., Pelayo-Terán J.M., Rodríguez-Sánchez J.M., Pérez-Iglesias R., González-Blanch C., et al. Reduced thalamic volume in first-episode non-affective psychosis: correlations with clinical variables, symptomatology and cognitive functioning. Neuroimage 2007, 35:1613-1623.
16. DeLisi L.E., Sakuma M., Maurizio A.M., Relja M., Hoff A.L. Cerebral ventricular change over the first 10years after the onset of schizophrenia. Psychiatry Res 2004, 130:57-70.
17. Dutt A., McDonald C., Dempster E., Prata D., Shaikh M., Williams I., et al. The effect of COMT, BDNF, 5-HTT, NRG1 and DTNBP1 genes on hippocampal and lateral ventricular volume in psychosis. Psychol Med 2009, 39:1783-1797.
18. Egan M.F., Kojima M., Callicott J.H., Goldberg T.E., Kolachana B.S., Bertolino A., et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003, 112:257-269.
19. Egan M.F., Weinberger D.R., Lu B. Schizophrenia, III: brain-derived neurotropic factor and genetic risk. Am J Psychiatry 2003, 160:1242.
20. Eisenberg D.P., Ianni A.M., Wei S.M., Kohn P.D., Kolachana B., Apud J., et al. Brain-derived neurotrophic factor (BDNF) Val(66)Met polymorphism differentially predicts hippocampal function in medication-free patients with schizophrenia. Mol Psychiatry 2013, [Jan 15]. 10.1038/mp.2012.187.
21. First M.B., Spitzer R.L., Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I Disorders: SCID-II: Clinician Version: Administration Booklet 1997, American Psychiatric Press.
22. Fusar-Poli P., Smieskova R., Serafini G., Politi P., Borgwardt S. Neuroanatomical markers of genetic liability to psychosis and first episode psychosis: a voxelwise meta-analytical comparison. World J Biol Psychiatry 2012, [Epub ahead of print 27 Jan 2012].
23. Gruber O., Hasan A., Scherk H., Wobrock T., Schneider-Axmann T., Ekawardhani S., et al. Association of the brain-derived neurotrophic factor val66met polymorphism with magnetic resonance spectroscopic markers in the human hippocampus: in vivo evidence for effects on the glutamate system. Eur Arch Psychiatry Clin Neurosci 2012, 262:23-31.
24. Grzywacz A., Samochowiec A., Ciechanowicz A., Samochowiec J. Family-based study of brain-derived neurotrophic factor (BDNF) gene polymorphism in alcohol dependence. Pharmacol Rep 2010, 62:938-941.
25. Gur R.E., Cowell P., Turetsky B.I., Gallacher F., Cannon T., Bilker W., et al. A follow-up magnetic resonance imaging study of schizophrenia. Relationship of neuroanatomical changes to clinical and neurobehavioral measures. Arch Gen Psychiatry 1998, 55:145-152.
26. Harris G., Andreasen N.C., Cizadlo T., Bailey J.M., Bockholt H.J., Magnotta V.A., et al. Improving tissue classification in MRI: a three-dimensional multispectral discriminant analysis method with automated training class selection. J Comput Assist Tomogr 1999, 23:144-154.
27. Ho B.-C., Milev P., O'Leary D.S., Librant A., Andreasen N.C., Wassink T.H. Cognitive and magnetic resonance imaging brain morphometric correlates of brain-derived neurotrophic factor Val66Met gene polymorphism in patients with schizophrenia and healthy volunteers. Arch Gen Psychiatry 2006, 63:731-740.
28. Ho B.-C., Andreasen N.C., Dawson J.D., Wassink T.H. Association between brain-derived neurotrophic factor Val66Met gene polymorphism and progressive brain volume changes in schizophrenia. Am J Psychiatry 2007, 164:1890-1899.
29. Hong C.-J., Liou Y.-J., Tsai S.-J. Effects of BDNF polymorphisms on brain function and behavior in health and disease. Brain Res Bull 2011, 86:287-297.
30. Hyman C., Hofer M., Barde Y.A., Juhasz M., Yancopoulos G.D., Squinto S.P., et al. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 1991, 350:230-232.
31. Janca A., Kastrup M., Katschnig H., López-Ibor J.J., Mezzich J.E., Sartorius N. The World Health Organization Short Disability Assessment Schedule (WHO DAS-S): a tool for the assessment of difficulties in selected areas of functioning of patients with mental disorders. Soc Psychiatry Psychiatr Epidemiol 1996, 31:349-354.
32. Jönsson E.G., Edman-Ahlbom B., Sillén A., Gunnar A., Kulle B., Frigessi A., et al. Brain-derived neurotrophic factor gene (BDNF) variants and schizophrenia: an association study. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:924-933.
33. Kawashima K., Ikeda M., Kishi T., Kitajima T., Yamanouchi Y., Kinoshita Y., et al. BDNF is not associated with schizophrenia: data from a Japanese population study and meta-analysis. Schizophr Res 2009, 112(1-3):72-79.
34. Koolschijn P.C.M.P., Van Haren N.E.M., Bakker S.C., Hoogendoorn M.L.C., Hulshoff Pol H.E., Kahn R.S. Effects of brain-derived neurotrophic factor Val66Met polymorphism on hippocampal volume change in schizophrenia. Hippocampus 2010, 20:1010-1017.
35. Li J., Das K., Fu G., Li R., Wu R. The Bayesian lasso for genome-wide association studies. Bioinformatics 2011, 27(4):516-523. [15].
36. Lieberman J., Chakos M., Wu H., Alvir J., Hoffman E., Robinson D., et al. Longitudinal study of brain morphology in first episode schizophrenia. Biol Psychiatry 2001, 49:487-499.
37. Lu B. BDNF and activity-dependent synaptic modulation. Learn Mem 2003, 10:86-98.
38. Magnotta V.A., Heckel D., Andreasen N.C., Cizadlo T., Corson P.W., Ehrhardt J.C., et al. Measurement of brain structures with artificial neural networks: two- and three-dimensional applications. Radiology 1999, 211:781-790.
39. Magnotta V.A., Harris G., Andreasen N.C., O'Leary D.S., Yuh W.T.C., Heckel D. Structural MR image processing using the BRAINS2 toolbox. Comput Med Imaging Graph 2002, 26:251-264.
40. Maisonpierre P.C., Le Beau M.M., Espinosa R., Ip N.Y., Belluscio L., De la Monte S.M., et al. Human and rat brain-derived neurotrophic factor and neurotrophin-3: gene structures, distributions, and chromosomal localizations. Genomics 1991, 10:558-568.
41. Matsushita S., Kimura M., Miyakawa T., Yoshino A., Murayama M., Masaki T., et al. Association study of brain-derived neurotrophic factor gene polymorphism and alcoholism. Alcohol Clin Exp Res 2004, 28(11):1609-1612.
42. Meyer-Lindenberg A. From maps to mechanisms through neuroimaging of schizophrenia. Nature 2010, 468:194-202.
43. Molendijk M.L., Bus B.A., Spinhoven P., Kaimatzoglou A., Oude Voshaar R.C., Penninx B.W., et al. A systematic review and meta-analysis on the association between BDNF val(66)met and hippocampal volume-a genuine effect or a winner's curse?. Am J Med Genet B Neuropsychiatr Genet 2012, 159B(6):731-740.
44. Montag C., Weber B., Fliessbach K., Elger C., Reuter M. The BDNF Val66Met polymorphism impacts parahippocampal and amygdala volume in healthy humans: incremental support for a genetic risk factor for depression. Psychol Med 2009, 39:1831-1839.
45. Nedic G., Nikolac Perkovic M., Nenadic Sviglin K., Muck-Seler D., Borovecki F., Pivac N. Brain-derived neurotrophic factor Val66Met polymorphism and alcohol-related phenotypes. Prog Neuropsychopharmacol Biol Psychiatry 2013, 40:193-198.
46. Olabi B., Ellison-Wright I., McIntosh A.M., Wood S.J., Bullmore E., Lawrie S.M. Are there progressive brain changes in schizophrenia? A meta-analysis of structural magnetic resonance imaging studies. Biol Psychiatry 2011, 70:88-96.
47. Overall J.E., Gorham D.R. The Brief Psychiatric Rating Scale. Psychol Rep 1962, 10:799-812.
48. Pantelis C., Velakoulis D., McGorry P.D., Wood S.J., Suckling J., Phillips L.J., et al. Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet 2003, 361:281-288.
49. Pelayo-Terán J.M., Pérez-Iglesias R., Ramírez-Bonilla M., González-Blanch C., Martínez-García O., Pardo-García G., et al. Epidemiological factors associated with treated incidence of first-episode non-affective psychosis in Cantabria: insights from the Clinical Programme on Early Phases of Psychosis. Early Interv Psychiatry 2008, 2:178-187.
50. Rakofsky J.J., Ressler K.J., Dunlop B.W. BDNF function as a potential mediator of bipolar disorder and post-traumatic stress disorder comorbidity. Mol Psychiatry 2012, 17(1):22-35. [Jan].
51. Rasanen S., Veijola J., Hakko H., Joukamaa M., Isohanni M. Gender differences in incidence and age at onset of DSM-III-R schizophrenia. Preliminary results of the Northern Finland 1966 birth cohort study. Schizophr Res 1999, 37:197-198.
52. Rizos E.N., Siafakas N., Stefanis N., Douzenis A., Kontaxakis V., Laskos E., et al. Association of serum BDNF and val66met polymorphism of the brain-derived neurotrophic factor in a sample of first psychotic episode patients. Psychiatrike 2009, 20:297-304.
53. Roiz-Santiáñez R., Ayesa-Arriola R., Tordesillas-Gutiérrez D., Ortiz-García de la Foz V., Pérez-Iglesias R., Pazosc A., et al. Three-year longitudinal population-based volumetric MRI study in first-episode schizophrenia-spectrum patients. Psychol Med 2013, [under review].
54. Schaufelberger M.S., Lappin J.M., Duran F.L.S., Rosa P.G.P., Uchida R.R., Santos L.C., et al. Lack of progression of brain abnormalities in first-episode psychosis: a longitudinal magnetic resonance imaging study. Psychol Med 2011, 41:1677-1689.
55. Shenton M.E., Dickey C.C., Frumin M., McCarley R.W. A review of MRI findings in schizophrenia. Schizophr Res 2001, 49:1-52.
56. Smith G.N., Thornton A.E., Lang D.J., Macewan G.W., Ehmann T.S., Kopala L.C., et al. Hippocampal volume and the brain-derived neurotrophic factor Val66Met polymorphism in first episode psychosis. Schizophr Res 2012, 134:253-259.
57. Sublette M.E., Baca-Garcia E., Parsey R.V., Oquendo M.A., Rodrigues S.M., Galfalvy H., et al. Effect of BDNF val66met polymorphism on age-related amygdala volume changes in healthy subjects. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1652-1655.
58. Sun M., Liu L., Yang L., Wang Y., Cui K., Wang L., et al. Association study of brain-derived neurotrophic factor Val66Met polymorphism and clinical characteristics of first episode schizophrenia. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2012, 29:155-158.
59. Szeszko P.R., Lipsky R., Mentschel C., Robinson D., Gunduz-Bruce H., Sevy S., et al. Brain-derived neurotrophic factor val66met polymorphism and volume of the hippocampal formation. Mol Psychiatry 2005, 10:631-636.
60. Takahashi T., Suzuki M., Tsunoda M., Kawamura Y., Takahashi N., Tsuneki H., et al. Association between the brain-derived neurotrophic factor Val66Met polymorphism and brain morphology in a Japanese sample of schizophrenia and healthy comparisons. Neurosci Lett 2008, 435(1):34-39. [11].
61. Van Haren N.E.M., Hulshoff Pol H.E., Schnack H.G., Cahn W., Brans R., Carati I., et al. Progressive brain volume loss in schizophrenia over the course of the illness: evidence of maturational abnormalities in early adulthood. Biol Psychiatry 2008, 63:106-113.
62. Van Os J., Kenis G., Rutten B.P.F. The environment and schizophrenia. Nature 2010, 468:203-212.
63. Vonesh E.F., Chinchilli V.M. Linear and nonlinear models for the analysis of repeated measure 1997, CRC Press.
64. Zakharyan R., Boyajyan A., Arakelyan A., Gevorgyan A., Mrazek F., Petrek M. Functional variants of the genes involved in neurodevelopment and susceptibility to schizophrenia in an Armenian population. Hum Immunol 2011, 72:746-748.
65. Zeng Y., Tan M., Kohyama J., Sneddon M., Watson J.B., Sun Y.E., et al. Epigenetic enhancement of BDNF signaling rescues synaptic plasticity in aging. J Neurosci 2011, 31:17800-17810.
66. Zhang L., Fang Y., Zeng Z., Lian Y., Wei J., Zhu H., et al. BDNF gene polymorphisms are associated with Alzheimer's disease-related depression and antidepressant response. J Alzheimers Dis 2011, 26(3):523-530.
67. Zhou D.H., Yan Q.Z., Yan X.M., Li C.B., Fang H., Zheng Y.L., et al. The study of BDNF Val66Met polymorphism in Chinese schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34(6):930-933. [Aug 16].
68. Zipursky R.B., Christensen B.K., Mikulis D.J. Stable deficits in gray matter volumes following a first episode of schizophrenia. Schizophr Res 2004, 71:515-516.